Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors - Wikidata - wikimedia - TriplyDB

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

http://www.wikidata.org/entity/Q29035867

about

Current understanding of interactions between nanoparticles and the immune system Optimal management of metastatic melanoma: current strategies and future directions Microtubule-binding agents: a dynamic field of cancer therapeutics.Clinical Translation of Nanomedicine.A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.Nanoparticles and the immune system Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines The history and future of chemotherapy for melanoma.Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.Facile fabrication of a magnetically smart PTX-loaded Cys-Fe3O4/CuS@BSA nano-drug for imaging-guided chemo-photothermal therapy.Taxol biosynthesis: Identification and characterization of two acetyl CoA:taxoid-O-acetyl transferases that divert pathway flux away from Taxol production.Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Novel therapeutics for the treatment of metastatic melanoma.Nab-paclitaxel in patients with metastatic melanoma.An imagable and photothermal "Abraxane-like" nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors.Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity.

P2860

Q26345204-B7B004B6-1D48-45F3-B806-6EFC38D8B3A0 Q26997338-FFEED5AF-8679-4F80-85D8-F92C1CB0E96A Q27690249-725931AA-DFB4-4D8A-9002-0C02FB51BD1B Q30355939-7D7F9F0B-7DE0-47F0-86E0-F2446470C3FD Q33394828-45B8198D-48D8-4299-B3B1-DAF44FE8ADF7 Q33406415-DB308280-4D0B-4AEE-B6C8-5AE556109480 Q33409023-2592C9AF-F9B0-4861-B1C1-45CA2F8DC3A3 Q33427359-0D88CF16-153C-4BB2-8BCD-19FD0EF7833A Q33634320-3057D67F-D6A0-4E4C-8E51-F25383330F9A Q33813555-3466E53E-5F5D-4E0E-9EA3-2A47A8A1B5B5 Q34045119-E9205BF8-A9CD-45A1-A4F6-803F161E953A Q34608084-382183B0-7A15-4EF3-8A65-9961ABC20C18 Q34781518-64FBDFCF-5A2E-4084-9A39-5543E67ABB04 Q34965672-7324F934-C8FA-4EC6-AE0A-D3763F4655DC Q36088022-C05F29B6-279B-43D9-B19B-8FBAE7FC15F9 Q36262241-D87F2304-1054-45DD-89F1-D9D2CEC22727 Q37357119-37DAF070-57A6-45CC-AE7F-8CD59A68D7F8 Q37442881-7DEBAAF4-D681-47FF-BF33-BAAC23A1465B Q37467770-8869342D-6E89-498C-8A1E-178A267464F8 Q37486788-4929558C-752F-4288-ADA3-4F111E9E6652 Q38625186-1F793331-87E1-4060-BC59-099F538969CF Q38928711-5DE5EB2B-0B9F-4AEB-B789-0A08EA3D3121 Q39826698-57315C2A-9D52-4DA4-A44E-EF1150ED2D03 Q39858166-87729A21-5650-40D2-8757-42591310C062 Q40005854-DE65731D-0175-491D-BFC1-116EB6BB1C91 Q42992197-55C0D6CB-9F93-41F4-AD42-BE66E90EC825 Q49058815-ACD97F85-E368-4133-B288-EE453E8B9239

P2860

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

http://www.wikidata.org/entity/Q29035867

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@ast

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@en

type

label

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@ast

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@en

prefLabel

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@ast

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@en

P1433

Q29035867-54FC35C1-C931-44C5-8737-B32F4DCECA35

P1476

Q29035867-12D1FA51-94B1-4135-9325-A5CEE3184BFF

P2093

Q29035867-16F7C60F-FD5E-4A08-BD62-3950388F5BD0

Q29035867-1B5248DB-3C1A-4168-A29F-7AC524827116

Q29035867-36BBA229-D180-4BF3-9330-10A6231B8449

Q29035867-3AC21582-2E73-4E8C-B406-44E03524A45A

Q29035867-4A6D6544-E71C-449A-8815-3EAFE4604319

Q29035867-4AC58432-B499-4472-BCEB-12120EDB4465

Q29035867-6862E4AF-C8BD-4673-9C40-1213784CFE45

Q29035867-6F2E2FA8-FC66-4E28-A179-6B2C1BBB2946

Q29035867-B00CA4C4-9C75-4172-BB35-3DD7A5F1F71D

Q29035867-B5F466A2-E045-4411-BFDC-5733F08D2189

P2860

Q29035867-34305AA5-3FA8-4C87-B9DB-8A3FC199EAF9

Q29035867-4792A67B-8099-4E7E-8948-8D99F6880DDB

Q29035867-4EBA8433-98BC-41B5-9D36-8695066D8B5F

Q29035867-5B245768-7B66-447F-A24D-09B85E927478

Q29035867-7A4B771C-06B7-4BB3-BC74-E1F605BC90BC

Q29035867-8DF0E744-4933-44BA-AC5E-081241BAD8E5

Q29035867-BC5FE914-C329-454F-B5D2-AAFB0305BF7A

Q29035867-BD704534-1F58-4AA4-B512-3D36679239C8

Q29035867-E3A528F4-42A7-47D1-A540-A763176DA0A2

Q29035867-E562EDE1-E77F-4227-9E94-89E36ECF8F3E

P2888

Q29035867-2B61CA01-C56A-4488-8EC6-3EC83D698351

P304

Q29035867-B5A6D80D-D560-4717-AFA9-F4DD90422D7E

P31

Q29035867-E61E2AEF-6850-4805-BA99-852C0523B612

P356

Q29035867-D526683B-D5EE-4F46-895E-867BC1B80801

P433

Q29035867-22162FFA-3862-4B00-9DCE-CA1770346972

P478

Q29035867-519258C9-71AF-4CFA-A505-2ECC362ACB8A

P577

Q29035867-1F3FDEBF-422D-45B1-B294-682190D34FBB

P5875

Q29035867-9BE600F5-93AD-4E9D-974B-138C0921C650

P6179

Q29035867-29943D8D-87CD-47B0-A8EF-FA676D459064

P698

Q29035867-6B6B0E90-EF13-47B9-BBCC-DC51532B7564

P921

Q29035867-31F8231C-7E3D-4A8F-AB06-8E6BA92E6731

Q29035867-57A415C0-CB5B-43EA-AD84-8E4FBAC838A1

P932

Q29035867-B640350B-D4AC-46D1-AACD-C8FC38CD2F8B

P356

S00280-007-0423-X

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I and pharmacokinetic tr ...... in patients with solid tumors

@en

P2093

Anastasia Ivanova

http://www.w3.org/2001/XMLSchema#string

Bert H. O’Neil

http://www.w3.org/2001/XMLSchema#string

Celeste Lindley

http://www.w3.org/2001/XMLSchema#string

Christine M. Walko

http://www.w3.org/2001/XMLSchema#string

E. Claire Dees

http://www.w3.org/2001/XMLSchema#string

Frances A. Collichio

http://www.w3.org/2001/XMLSchema#string

Hua Mu

http://www.w3.org/2001/XMLSchema#string

Mark A. Socinski

http://www.w3.org/2001/XMLSchema#string

Michael J. Hawkins

http://www.w3.org/2001/XMLSchema#string

Richard M. Goldberg

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

The taxanes: an update.

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

P2888

s00280-007-0423-x

P304

759-766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-007-0423-X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6520061

http://www.w3.org/2001/XMLSchema#string

P6179

1043873275

http://www.w3.org/2001/XMLSchema#string

P698

17285317

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

phase I clinical trial

P932

2860386

http://www.w3.org/2001/XMLSchema#string